273 related articles for article (PubMed ID: 24532039)
1. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
3. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
5. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
7. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
Deininger MW; Kopecky KJ; Radich JP; Kamel-Reid S; Stock W; Paietta E; Emanuel PD; Tallman M; Wadleigh M; Larson RA; Lipton JH; Slovak ML; Appelbaum FR; Druker BJ
Br J Haematol; 2014 Jan; 164(2):223-32. PubMed ID: 24383843
[TBL] [Abstract][Full Text] [Related]
8. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
[TBL] [Abstract][Full Text] [Related]
9. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
Saavedra D; Vizcarra F
Leuk Lymphoma; 2014 Dec; 55(12):2813-6. PubMed ID: 24724785
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
[TBL] [Abstract][Full Text] [Related]
11. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
12. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
13. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
[TBL] [Abstract][Full Text] [Related]
14. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
[TBL] [Abstract][Full Text] [Related]
15. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K; Miyamoto T; Tanimoto M; Yamamoto K; Kimura S; Kawaguchi T; Matsumura I; Hata T; Tsurumi H; Saito S; Hino M; Tadokoro S; Meguro K; Hyodo H; Yamamoto M; Kubo K; Tsukada J; Kondo M; Aoki M; Okada H; Yanada M; Ohyashiki K; Taniwaki M
Leuk Res; 2016 Dec; 51():11-18. PubMed ID: 27771544
[TBL] [Abstract][Full Text] [Related]
16. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Baccarani M; Druker BJ; Branford S; Kim DW; Pane F; Mongay L; Mone M; Ortmann CE; Kantarjian HM; Radich JP; Hughes TP; Cortes JE; Guilhot F
Int J Hematol; 2014; 99(5):616-24. PubMed ID: 24658916
[TBL] [Abstract][Full Text] [Related]
17. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Kantarjian HM; Giles FJ; Bhalla KN; Pinilla-Ibarz J; Larson RA; Gattermann N; Ottmann OG; Hochhaus A; Radich JP; Saglio G; Hughes TP; Martinelli G; Kim DW; Shou Y; Gallagher NJ; Blakesley R; Baccarani M; Cortes J; le Coutre PD
Blood; 2011 Jan; 117(4):1141-5. PubMed ID: 21098399
[TBL] [Abstract][Full Text] [Related]
19. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]